Works matching IS 03407004 AND DT 2024 AND VI 73 AND IP 12

Results: 34

Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis.

Published in:

2024

By:

Chen, Yueying;
Han, Hedong;
Cheng, Jing;
Cheng, Qinpei;
Zhu, Suhua;
Zhan, Ping;
Liu, Hongbing;
Song, ·Yong;
Lv, Tangfeng

Publication type:

Correction Notice

Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03852-w

By:

Kim, Hye In;
Kim, Won Gu;
Kim, Mijin;
Ko, Nak Gyeong;
Jin, Mihyeon;
Jung, Hyun Ae;
Sun, Jong-Mu;
Ahn, Jin Seok;
Ahn, Myung-Ju;
Choi, Yoon-La;
Jeon, Min Ji;
Kim, Tae Yong;
Kim, Won Bae;
Kim, Sang-We;
Lee, Dae Ho;
Jang, Se Jin;
Kim, Sun Wook;
Chung, Jae Hoon;
Kim, Tae Hyuk;
Lee, Se-Hoon

Publication type:

Article

Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03852-w

By:

Kim, Hye In;
Kim, Won Gu;
Kim, Mijin;
Ko, Nak Gyeong;
Jin, Mihyeon;
Jung, Hyun Ae;
Sun, Jong-Mu;
Ahn, Jin Seok;
Ahn, Myung-Ju;
Choi, Yoon-La;
Jeon, Min Ji;
Kim, Tae Yong;
Kim, Won Bae;
Kim, Sang-We;
Lee, Dae Ho;
Jang, Se Jin;
Kim, Sun Wook;
Chung, Jae Hoon;
Kim, Tae Hyuk;
Lee, Se-Hoon

Publication type:

Article

Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03844-w

By:

Han, Yuelin;
Xiao, Xiangtian;
Qin, Tingting;
Yao, Shuxi;
Liu, Xinyue;
Feng, Yanqi;
Li, Zhou;
Li, Yiming;
Xia, Shu

Publication type:

Article

Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03844-w

By:

Han, Yuelin;
Xiao, Xiangtian;
Qin, Tingting;
Yao, Shuxi;
Liu, Xinyue;
Feng, Yanqi;
Li, Zhou;
Li, Yiming;
Xia, Shu

Publication type:

Article

Optimizing cancer classification: a hybrid RDO-XGBoost approach for feature selection and predictive insights.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03843-x

By:

Yaqoob, Abrar;
Verma, Navneet Kumar;
Aziz, Rabia Musheer;
Shah, Mohd Asif

Publication type:

Article

Optimizing cancer classification: a hybrid RDO-XGBoost approach for feature selection and predictive insights.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03843-x

By:

Yaqoob, Abrar;
Verma, Navneet Kumar;
Aziz, Rabia Musheer;
Shah, Mohd Asif

Publication type:

Article

Integrative analyses of bulk and single-cell RNA-seq reveals the correlation between SPP1+ macrophages and resistance to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03848-6

By:

Geng, Zhenyang;
Li, Feng;
Yang, Zhichang;
Li, Bowen;
Xu, Yifan;
Wu, Bin;
Sheng, Yinliang;
Yuan, Ping;
Huang, Lan;
Qi, Yu

Publication type:

Article

Integrative analyses of bulk and single-cell RNA-seq reveals the correlation between SPP1+ macrophages and resistance to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03848-6

By:

Geng, Zhenyang;
Li, Feng;
Yang, Zhichang;
Li, Bowen;
Xu, Yifan;
Wu, Bin;
Sheng, Yinliang;
Yuan, Ping;
Huang, Lan;
Qi, Yu

Publication type:

Article

Correction to: Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody.

Published in:

2024

By:

Yuan, Shijin;
Xia, Yan;
Shen, Lihong;
Ye, Liuqing;
Li, Lisha;
Chen, Lifen;
Xie, Xinyou;
Lou, Haizhou;
Zhang, Jun

Publication type:

Correction Notice

Correction to: Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody.

Published in:

2024

By:

Yuan, Shijin;
Xia, Yan;
Shen, Lihong;
Ye, Liuqing;
Li, Lisha;
Chen, Lifen;
Xie, Xinyou;
Lou, Haizhou;
Zhang, Jun

Publication type:

Correction Notice

Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03808-0

By:

Tachi, Tetsuro;
Kijima, Noriyuki;
Kuroda, Hideki;
Ikeda, Syunya;
Murakami, Koki;
Nakagawa, Tomoyoshi;
Yaga, Moto;
Nakagawa, Kanji;
Utsugi, Reina;
Hirayama, Ryuichi;
Okita, Yoshiko;
Kagawa, Naoki;
Kishima, Haruhiko;
Imai, Chihaya;
Hosen, Naoki

Publication type:

Article

Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03808-0

By:

Tachi, Tetsuro;
Kijima, Noriyuki;
Kuroda, Hideki;
Ikeda, Syunya;
Murakami, Koki;
Nakagawa, Tomoyoshi;
Yaga, Moto;
Nakagawa, Kanji;
Utsugi, Reina;
Hirayama, Ryuichi;
Okita, Yoshiko;
Kagawa, Naoki;
Kishima, Haruhiko;
Imai, Chihaya;
Hosen, Naoki

Publication type:

Article

Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03803-5

By:

Gradone, Allison L.;
Ma, Vincent T.;
Vasbinder, Alexi;
Fecher, Leslie A.;
Yentz, Sarah;
Hayek, Salim S.;
Lao, Christopher D.

Publication type:

Article

Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03803-5

By:

Gradone, Allison L.;
Ma, Vincent T.;
Vasbinder, Alexi;
Fecher, Leslie A.;
Yentz, Sarah;
Hayek, Salim S.;
Lao, Christopher D.

Publication type:

Article

Immunotherapy may be more appropriate for ERBB2 low-expressing extramammary paget's disease patients: a prognosis analysis and exploration of targeted therapy and immunotherapy of extramammary paget's disease patients.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03846-8

By:

Yang, Jiawen;
Chen, Yurong;
Zhang, Xiuyuan;
Tong, Ziyan;
Weng, Shanshan;
Zhu, Ning;
Yuan, Ying

Publication type:

Article

Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03842-y

By:

Reimann, Patrick;
Mavroeidi, Ilektra-Antonia;
Burghofer, Jonathan;
Taghizadeh, Hossein;
Webersinke, Gerald;
Kasper, Stefan;
Schreil, Georg;
Morariu, Darius;
Reichinger, Andreas;
Baba, Hideo Andreas;
Kirchweger, Patrick;
Schuler, Martin;
Djanani, Angela;
Prager, Gerald W.;
Rumpold, Holger;
Benda, Magdalena;
Schneider, Eva-Maria;
Mink, Sylvia;
Winder, Thomas;
Doleschal, Bernhard

Publication type:

Article

Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03841-z

By:

Wang, Shanshan;
Chao, Jiashuo;
Wang, Hao;
Li, Shuofeng;
Wang, Yunchao;
Zhu, Chengpei;
Zhang, Nan;
Piao, Mingjian;
Yang, Xu;
Liu, Kai;
Xun, Ziyu;
Sang, Xinting;
Yang, Xiaobo;
Duan, Weidong;
Zhao, Haitao

Publication type:

Article

Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphoma.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03840-0

By:

Chen, Xinrui;
Qin, Yan;
Xue, Xuemin;
Xie, Zucheng;
Xie, Tongji;
Huang, Liling;
Zhu, Haohua;
Gao, Lina;
Li, Jiangtao;
Yang, Jianliang;
Gui, Lin;
Yang, Sheng;
Chen, Haizhu;
Feng, Xiaoli;
Shi, Yuankai

Publication type:

Article

Enhanced anti-tumor efficacy of electroporation (EP)-mediated DNA vaccine boosted by allogeneic lymphocytes in pre-established tumor models.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03838-8

By:

Shi, Sanyuan;
Zhang, Luchen;
Zheng, Anjie;
Xie, Fang;
Kesse, Samuel;
Yang, Yang;
Peng, Jinliang;
Xu, Yuhong

Publication type:

Article

PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03837-9

By:

Blobner, Jens;
Dengler, Laura;
Eberle, Constantin;
Herold, Julika J.;
Xu, Tao;
Beck, Alexander;
Mühlbauer, Anton;
Müller, Katharina J.;
Teske, Nico;
Karschnia, Philipp;
van den Heuvel, Dominic;
Schallerer, Ferdinand;
Ishikawa-Ankerhold, Hellen;
Thon, Niklas;
Tonn, Joerg-Christian;
Subklewe, Marion;
Kobold, Sebastian;
Harter, Patrick N.;
Buchholz, Veit R.;
von Baumgarten, Louisa

Publication type:

Article

Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03836-w

By:

De Giglio, Andrea;
Leonetti, Alessandro;
Comito, Francesca;
Filippini, Daria Maria;
Mollica, Veronica;
Rihawi, Karim;
Peroni, Marianna;
Mazzaschi, Giulia;
Ricciotti, Ilaria;
Carosi, Francesca;
Marchetti, Andrea;
Rosellini, Matteo;
Gagliano, Ambrogio;
Favorito, Valentina;
Nobili, Elisabetta;
Gelsomino, Francesco;
Melotti, Barbara;
Marchese, Paola Valeria;
Sperandi, Francesca;
Di Federico, Alessandro

Publication type:

Article

INTASYL self-delivering RNAi decreases TIGIT expression, enhancing NK cell cytotoxicity: a potential application to increase the efficacy of NK adoptive cell therapy against cancer.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03835-x

By:

Maxwell, Melissa;
Yan, Dingxue;
Rivest, Brianna;
Boone, Andrew;
Cardia, James;
Noessner, Elfriede

Publication type:

Article

PD-L1+ neutrophils induced NETs in malignant ascites is a potential biomarker in HCC.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03833-z

By:

Sun, Xiaoyu;
Gui, Yaoqi;
Yang, Tai;
Chen, Lingbing;
Zhang, Yi;
Yan, Ling;
Chen, Weixian;
Wang, Bo

Publication type:

Article

Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03831-1

By:

Tan, Yang;
Liu, Kai;
Zhu, Chengpei;
Wang, Shanshan;
Wang, Yunchao;
Xue, Jingnan;
Ning, Cong;
Zhang, Nan;
Chao, Jiashuo;
Zhang, Longhao;
Long, Junyu;
Yang, Xiaobo;
Zeng, Daobing;
Zhao, Lijin;
Zhao, Haitao

Publication type:

Article

NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03830-2

By:

Zhang, Wanli;
Shi, Xupeiyao;
Huang, Shitong;
Yu, Qiumin;
Wu, Zijie;
Xie, Wenbin;
Li, Binghua;
Xu, Yanchao;
Gao, Zheng;
Li, Guozhi;
Qian, Qianqian;
He, Tiandi;
Zheng, Jiaxue;
Zhang, Tingran;
Tong, Yue;
Deng, Danni;
Gao, Xiangdong;
Tian, Hong;
Yao, Wenbing

Publication type:

Article

A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03829-9

By:

Jiang, Yuxin;
Chen, Yueying;
Cheng, Qinpei;
Lu, Wanjun;
Li, Yu;
Zuo, Xueying;
Wu, Qiuxia;
Wang, Xiaoxia;
Zhang, Fang;
Wang, Dong;
Wang, Qin;
Lv, Tangfeng;
Song, Yong;
Zhan, Ping

Publication type:

Article

Tumor immunogenicity regulates host immune responses, and conventional dendritic cell type 2 uptakes the majority of tumor antigens in an orthotopic lung cancer model.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03828-w

By:

Kim, Ki-Hyun;
Kim, Seung-jae;
Eccles, Jacob D.;
Ascoli, Christian;
Park, Gye Young

Publication type:

Article

The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03824-0

By:

Chan, Chilam;
Cabanes, Núria Casalé;
Jansen, J. H. Marco;
Guillaume, Joël;
Nederend, Maaike;
Passchier, Elsemieke M.;
Gómez-Mellado, Valentina E.;
Peipp, Matthias;
Boes, Marianne;
van Tetering, Geert;
Leusen, Jeanette H. W.

Publication type:

Article

Toripalimab combined with definitive chemoradiotherapy for locally advanced cervical squamous cell carcinoma patients (TRACE): A single-arm, phase I/II trial.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03823-1

By:

Ou, Dan;
Cai, Rong;
Qi, Wei-Xiang;
Cui, Can;
Cao, Lu;
Wang, Shu-Bei;
Li, Huan;
Ma, Tao;
Miao, Ying;
Xu, Cheng;
Cai, Gang;
Cao, Wei-Guo;
Gao, Yun-Sheng;
Chen, Jia-Yi;
Xu, Hao-Ping

Publication type:

Article

GPCRs: emerging targets for novel T cell immune checkpoint therapy.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03801-7

By:

Dickinson, Kaitlyn;
Yee, Elliott J.;
Vigil, Isaac;
Schulick, Richard D.;
Zhu, Yuwen

Publication type:

Article

HLA-G neo-expression modifies genetic programs governing tumor cell lines.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03768-5

By:

Tronik-Le Roux, Diana;
Daouya, Marina;
Poras, Isabelle;
Desgrandchamps, François;
Carosella, Edgardo D.

Publication type:

Article

Dose-escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E) against chemotherapy-resistant malignant pleural mesothelioma: a clinical trial.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03815-1

By:

Sakura, Kazuma;
Kuroyama, Muneyoshi;
Shintani, Yasushi;
Funaki, Soichiro;
Atagi, Shinji;
Kadota, Yoshihisa;
Kuribayashi, Kozo;
Kijima, Takashi;
Nakano, Takashi;
Nakajima, Toshihiro;
Sasai, Masao;
Okumura, Meinoshin;
Kaneda, Yasufumi

Publication type:

Article

Therapeutic antibodies in oncology: an immunopharmacological overview.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03814-2

By:

Toledo-Stuardo, Karen;
Ribeiro, Carolina H.;
González-Herrera, Fabiola;
Matthies, Douglas J.;
Le Roy, María Soledad;
Dietz-Vargas, Claudio;
Latorre, Yesenia;
Campos, Ivo;
Guerra, Yuneisy;
Tello, Samantha;
Vásquez-Sáez, Valeria;
Novoa, Pedro;
Fehring, Nicolás;
González, Mauricio;
Rodríguez-Siza, Jose;
Vásquez, Gonzalo;
Méndez, Pamela;
Altamirano, Claudia;
Molina, María Carmen

Publication type:

Article

Works matching IS 03407004 AND DT 2024 AND VI 73 AND IP 12

Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis.

Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer.

Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer.

Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis.

Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis.

Optimizing cancer classification: a hybrid RDO-XGBoost approach for feature selection and predictive insights.

Optimizing cancer classification: a hybrid RDO-XGBoost approach for feature selection and predictive insights.

Integrative analyses of bulk and single-cell RNA-seq reveals the correlation between SPP1<sup>+</sup> macrophages and resistance to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.

Integrative analyses of bulk and single-cell RNA-seq reveals the correlation between SPP1<sup>+</sup> macrophages and resistance to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.

Correction to: Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody.

Correction to: Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody.

Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model.

Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model.

Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era.

Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era.

Immunotherapy may be more appropriate for ERBB2 low-expressing extramammary paget's disease patients: a prognosis analysis and exploration of targeted therapy and immunotherapy of extramammary paget's disease patients.

Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data.

Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study.

Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphoma.

Enhanced anti-tumor efficacy of electroporation (EP)-mediated DNA vaccine boosted by allogeneic lymphocytes in pre-established tumor models.

PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis.

Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy.

INTASYL self-delivering RNAi decreases TIGIT expression, enhancing NK cell cytotoxicity: a potential application to increase the efficacy of NK adoptive cell therapy against cancer.

PD-L1<sup>+</sup> neutrophils induced NETs in malignant ascites is a potential biomarker in HCC.

Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.

NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy.

A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients.

Tumor immunogenicity regulates host immune responses, and conventional dendritic cell type 2 uptakes the majority of tumor antigens in an orthotopic lung cancer model.

The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy.

Toripalimab combined with definitive chemoradiotherapy for locally advanced cervical squamous cell carcinoma patients (TRACE): A single-arm, phase I/II trial.

GPCRs: emerging targets for novel T cell immune checkpoint therapy.

HLA-G neo-expression modifies genetic programs governing tumor cell lines.

Dose-escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E) against chemotherapy-resistant malignant pleural mesothelioma: a clinical trial.

Therapeutic antibodies in oncology: an immunopharmacological overview.